Skip to content
OpenCapital
Get started

Myriad Genetics MYGN Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net

Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net at other companies

Arcus Biosciences logo
Arcus BiosciencesRCUS
——

Other financials

Income statement

See full
Revenue$200.4M+2.3%
Gross profit$137.6M+2.5%
Operating income-$30.7M-5.9%
Net income-$34.1M-34,000%
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$126.0M+24.8%
Total debt$211.5M+34.2%
Total equity$337.4M-52.1%
Total assets$673.7M-33.0%

Cash flow

See full
Operating cash flow-$15.7M+3.7%
CapEx$18.8M+181%
Free cash flow-$19.7M+65.1%

Valuation

See full
Market cap$512.85M+13.1%
Enterprise value$598.35M+17.3%
P/S0.6×+0.1×

Profitability

See full
Gross margin70%0.0pp
Operating margin-46.9%-88.3pp
Net margin-48.2%-72.9pp
FCF margin-17%—

Returns & leverage

See full
Return on equity-76.7%-98.4pp
Debt / equity0.6×+0.4×
Current ratio2.4×+0.5×

Where this comes from

Reported directly by Myriad Genetics in its filing.

Tagged under the XBRL concept us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet.

The official record: Myriad Genetics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Myriad Genetics's debt instrument, unamortized discount (premium) and debt issuance costs, net.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Myriad Genetics's debt instrument, unamortized discount (premium) and debt issuance costs, net?
Myriad Genetics (MYGN) reported debt instrument, unamortized discount (premium) and debt issuance costs, net of $8.5M in Q1 2026.